MHRA Issues Warning to Cardiac Patients Over Febuxostat

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned patients with cardiac conditions to avoid taking Febuxostat (adenuric).

Febuxostat is an oral drug used to treat patients with high levels of uric acid in the blood. MHRA said that patients with pre-existing major cardiovascular diseases shouldn’t use the drug unless they have no other options.

MHRA issued the warning based on a phase 4 clinical study in patients with gout or a history of other cardiovascular diseases that showed a higher risk of cardiovascular-related death and all-cause mortality in patients taking Febuxostat compared to patients taking allopurinol.